Summit Therapeutics SMMT Change in AP
Change in AP at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsPayable.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's change in ap.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's change in AP?
- Summit Therapeutics (SMMT) reported change in AP of $6.8M in Q1 2026.
- How has Summit Therapeutics's change in AP changed year-over-year?
- Summit Therapeutics's change in AP increased by 1810.7% year-over-year, from $356K to $6.8M.
- What does change in AP mean?
- The change in the amount of money the company owes to its suppliers.
- How do you interpret change in AP?
- An increase suggests the company is delaying payments to preserve cash, while a decrease indicates the company is paying down its obligations.
- How does change in AP compare across companies?
- Standard working capital metric; peers in biopharma often show fluctuations based on clinical trial vendor payment cycles.